FDA Clears Dexcom Stelo as First OTC CGM for Adults 18 and Older Not Using Insulin

FDA Clears First Over-the-Counter Continuous Glucose Monitor

The FDA cleared the Dexcom Stelo Glucose Biosensor System on March 5, 2024. This marks the first time a continuous glucose monitor becomes available for sale without a prescription. The device targets adults 18 years and older who do not use insulin. It supplies interstitial glucose readings every 15 minutes through a sensor worn on the upper arm and a compatible smartphone app.

Diabetes affects roughly 422 million adults worldwide. Regular monitoring supports effective management and helps lower the chance of complications. [2]

What this means

This clearance lets approved users buy the sensor without a clinician visit first. They gain access to frequent glucose data points on their phones. It shifts earlier rules that placed all continuous glucose monitors behind a prescription requirement.

Key takeaways

• The FDA cleared the Dexcom Stelo Glucose Biosensor System on March 5, 2024, as the first over-the-counter continuous glucose monitor. [1]
• The device is indicated for adults 18 years and older who do not use insulin. [1]
• It delivers glucose readings from interstitial fluid every 15 minutes via a sensor and compatible smartphone app. [1]
• Approximately 422 million adults worldwide have diabetes. [2]
• The FDA determined the device met safety and effectiveness standards for its intended non-prescription population. [1]

The Dexcom Stelo sensor attaches to the upper arm. It measures glucose in interstitial fluid instead of blood and sends updates to a smartphone application.

FDA staff reviewed information on device accuracy, how well non-professionals could operate it, and safety data for the stated group. They granted authorization through the de novo pathway. That process sets new classification and controls for similar low- to moderate-risk devices that lack direct predicates. [1]

Diabetes covers several conditions that change how the body handles blood glucose. Type 2 diabetes represents most cases. Many people manage it with lifestyle changes or non-insulin treatments. [3] The National Institute of Diabetes and Digestive and Kidney Diseases explains that tracking glucose patterns can shape daily decisions. [3]

The World Health Organization reports that consistent diabetes management lowers risks of heart disease, kidney failure, and vision loss. [2] Continuous glucose monitors produce more data points than traditional fingerstick tests.

Limitations

Clearance is limited to non-insulin-using adults 18 and older. Prescription CGMs remain the standard for insulin users and younger populations. The announcement reflects pre-market review. Long-term real-world performance and adherence data will emerge from post-market surveillance. Sources focus on regulatory and high-level disease context. Specific comparative effectiveness trials versus other CGMs are not detailed in the primary announcement. Clinical interpretation and integration into diabetes care still require individualized healthcare provider guidance.

Sources / References

[1] FDA Clears First Over-the-Counter Continuous Glucose Monitor - https://www.fda.gov/news-events/press-announcements/fda-clears-first-over-counter-continuous-glucose-monitor

[2] Diabetes - https://www.who.int/news-room/fact-sheets/detail/diabetes

[3] Diabetes Overview - https://www.niddk.nih.gov/health-information/diabetes/overview/what-is-diabetes